SAVE Moms and Babies Act of 2026
- Sponsor
- Sen. Hyde-Smith, Cindy [R-MS]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jan 27, 2026
Bottom line
This bill seeks to significantly restrict access to medication abortion by preventing new approvals and imposing stringent new requirements on existing drugs, effectively limiting their availability and use.
What it actually does
This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit the FDA from approving any new abortion drugs or granting investigational use exemptions for them. For abortion drugs already approved, it imposes strict new regulatory requirements, including prohibiting use after 70 days gestation, mandating in-person dispensing by the prescribing practitioner, and requiring a comprehensive Risk Evaluation and Mitigation Strategy (REMS) with specific certification and reporting obligations.
Proponents argue
Supporters argue the bill protects women's health and unborn children by ensuring abortion drugs are not approved without rigorous safety protocols and by restricting their availability to prevent complications. They emphasize the need for in-person medical supervision, accurate gestational assessment, and comprehensive reporting of adverse events to safeguard patients.
Opponents contend
Opponents contend the bill is an attempt to ban medication abortion under the guise of safety, arguing that it would severely limit access to a safe and effective medical procedure, disproportionately affecting women in rural areas and those with limited healthcare access. They assert that existing FDA regulations are sufficient and that the new requirements are medically unnecessary and burdensome.
The bill is relatively short and straightforward to read, allowing for a quick understanding of its core provisions.
Section 2(a), amending Section 505(bb)(1) of the Federal Food, Drug, and Cosmetic Act.
Prohibition on New Abortion Drug Approvals and Research Exemptions
This provision prohibits the Secretary of the FDA from approving any new applications for marketing abortion drugs and from granting investigational use exemptions for abortion drugs or any investigation that knowingly destroys an unborn child. This effectively halts the development and introduction of new medication abortion options.
Supporters argue
Supporters argue this protects unborn life and prevents the expansion of abortion access through new drug approvals, aligning with their view that abortion is morally wrong. They may also argue it prevents the introduction of potentially unsafe drugs.
Critics contend
Opponents contend this provision is a direct attack on reproductive healthcare access and scientific research, limiting future medical advancements and patient options. They assert it is ideologically driven rather than based on scientific safety concerns.
Tradeoffs
Balances the protection of unborn life and perceived safety concerns against the advancement of medical science and access to reproductive healthcare options.
Section 2(a), amending Section 505(bb)(2) of the Federal Food, Drug, and Cosmetic Act.
Enhanced Regulatory Requirements for Previously Approved Abortion Drugs
This provision imposes several new requirements on abortion drugs already approved before the bill's enactment. It prohibits labeling changes to approve use after 70 days gestation or dispensing by any means other than in-person administration by the prescribing practitioner. It also mandates that these drugs be treated as prescription-only and requires a stringent Risk Evaluation and Mitigation Strategy (REMS).
Section 2(a), amending Section 505(bb)(2)(C) of the Federal Food, Drug, and Cosmetic Act.
Mandatory Risk Evaluation and Mitigation Strategy (REMS) Components
This provision details the minimum requirements for the REMS for existing abortion drugs. It mandates certification for prescribing practitioners, requiring them to assess pregnancy duration, diagnose ectopic pregnancies, provide surgical intervention for complications, ensure patient access to blood transfusions/resuscitation, and report adverse events. It also limits dispensing to in-person administration in clinics/medical offices/hospitals, prohibits pharmacy dispensing, and requires patient acknowledgment of complication risks.
Section 2(a), amending Section 505(bb)(2)(C)(v), (bb)(2)(C)(vi), and (bb)(3) of the Federal Food, Drug, and Cosmetic Act.
Expanded Adverse Event and Administration Reporting
The bill requires manufacturers and prescribers to report all known adverse events (defined to include fatality, ectopic pregnancy, hospitalization, blood loss requiring transfusion, and various infections) to the FDA and manufacturer, excluding identifiable patient information. It also mandates reporting of abortion drug administration in the same manner as surgical abortions, or as required by state law. Furthermore, all other healthcare practitioners are required to report any patient adverse events connected to abortion drug use to the FDA.
Section 2(b).
Sunset for Existing Investigational Use Exemptions
This provision states that any investigational use exemption for a drug granted before the bill's enactment is automatically rescinded three years after enactment if the Secretary would be prohibited from granting such an exemption under the new Section 505(bb)(1)(B). This means ongoing research into abortion drugs would be terminated after a three-year grace period.
Defines "abortion drug" broadly as any drug, substance, or combination intended or used to intentionally kill an unborn child or terminate a pregnancy, with exceptions only for producing a live birth, removing a dead unborn child, or treating an ectopic pregnancy. This broad definition captures any drug used for medication abortion, regardless of its primary labeling.
Section 2(a), amending Section 505(bb)(5)(A).
Why it matters:Standard legislative practice to place definitions at the end of a section, but its broad scope is critical to the bill's overall effect.
Case for: Proponents would argue this definition is necessary to prevent circumvention of the bill's intent by re-labeling or repurposing drugs for abortion. It ensures comprehensive coverage of all substances used for this purpose.
Case against: Opponents might argue the broad definition could inadvertently capture drugs with other primary uses if they are ever used off-label to terminate a pregnancy, potentially leading to unintended regulatory burdens or restrictions on those drugs.
Estimated impact: Ensures the bill's prohibitions and restrictions apply to all current and future medication abortion methods.
Provides an expansive list of what constitutes an "adverse event" for reporting purposes, including fatality, ectopic pregnancy, hospitalization, blood loss requiring transfusion, and various infections (endometritis, pelvic inflammatory disease, pelvic infections with sepsis, severe infection).
Section 2(a), amending Section 505(bb)(5)(B).
Why it matters:Standard for definitions, but the specific inclusions are critical to the reporting burden and the data collected.
Case for: Proponents argue this detailed definition ensures comprehensive data collection on all potential complications, allowing for a more accurate assessment of drug safety and informing public health policy.
Case against: Opponents might argue that some listed events, like ectopic pregnancy, are not direct "adverse events" of the drug itself but rather conditions that the drug might fail to treat (if used for ectopic pregnancy) or that occur independently of drug use, potentially inflating perceived risks.
Estimated impact: Significantly expands the scope of required reporting for healthcare practitioners and manufacturers, potentially leading to a higher reported incidence of "adverse events."